Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Wave Life Sciences Ltd.NASDAQ: WVE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.46M fell 32.3% year over year, behind the -5.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 35.3% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.
Context
- Depreciation & amortization amounted to 20.7% of revenue in FY2025, up 12.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -32.3% toward the trailing-twelve-month pace of -5.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 8.85M USD
- Year-over-year change
- +2.2%
- 4-year CAGR
- -2.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.85M | +2.2% |
| FY2024 | 2024-12-31 | 8.66M | -5.9% |
| FY2023 | 2023-12-31 | 9.21M | -9.0% |
| FY2022 | 2022-12-31 | 10.11M | +2.8% |
| FY2021 | 2021-12-31 | 9.84M | — |
Depreciation & Amortization vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.8% is the 9th highest of 10, against a peer median of +9.0%.
- Depreciation & amortization amounts to 11.4% of revenue for WVE, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $54.76M USD | -3.1% | +7.8% | 1.1% | |
| LTM Mar 2026 | $45.14M USD | +15.9% | +2.1% | 2.1% | |
| LTM Sep 2026 | $28.19M USD | +36.7% | +0.9% | 2.9% | |
| LTM Sep 2026 | $26.62M USD | +11.3% | +28.7% | 5.9% | |
| LTM Mar 2026 | $9.99M USD | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $8.15M USD | -5.8% | -4.3% | 11.4% | |
| LTM Mar 2026 | $2.88M USD | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| LTM Mar 2026 | $2.28M USD | +9.0% | +4.6% | 7.1% | |
| LTM Mar 2026 | $885K USD | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $475K USD | +28.7% | +0.3% | — | |
| Peer median (excluding WVE) | — | +9.0% | +3.3% | 6.4% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| Deferred Income Tax | (12.64M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.41M | 17.19M | 9.8M | 13.14M | 0 |
| Change in Working Capital | 7.01M | 6.72M | 19.08M | (75.82M) | (16.94M) |
| Accounts Receivables | 30M | 0 | (21.09M) | 19.66M | 146K |
| Inventory | 2.04M | 0 | 0 | 0 | 0 |
| Accounts Payables | (6.57M) | 9.35M | (3.76M) | 3.42M | (561K) |
| Other Working Capital | (18.46M) | (2.63M) | 43.93M | (98.91M) | (16.53M) |
| Other Non-Cash Items | 12.64M | 12K | 0 | 0 | 24.97M |
| Operating Cash Flow | (88.99M) | (127.78M) | (19.43M) | (151.03M) | (187.49M) |
| Capital Expenditures | (560K) | (1.36M) | (1.12M) | (938K) | (718K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (75.04M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 75.04M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 106K | 0 | 0 | 0 |
| Investing Cash Flow | (560K) | (1.26M) | (1.12M) | (938K) | (718K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 54.97M | 52.33M | 131.28M | 236.18M | 488.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 858K | 14.86M | 1.26M | 17.71M | 0 |
| Financing Cash Flow | 55.83M | 67.19M | 132.53M | 253.89M | 488.24M |
| Effect of Forex Changes | (208K) | (210K) | (95K) | (138K) | 12K |
| Net Change in Cash | (33.93M) | (62.06M) | 111.89M | 101.79M | 300.04M |
| Free Cash Flow | (89.55M) | (129.14M) | (20.55M) | (151.96M) | (187.49M) |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.